T cell epitope peptide of Oratosquilla oratoria allergen tropomyosin and application of T cell epitope peptide

Through bioinformatics prediction and experiment identification of mantis shrimp T cell epitope peptides, designing T cell epitope tandem peptides, solving the hypoallergenicity problem of shrimp allergy treatment in the existing technology, and achieving effective targeting shrimp allergy Immune tolerance and desensitization effects.

CN119080902APending Publication Date: 2024-12-06XIAMEN OCEAN VOCATIONAL & TECH COLLEGE
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411222268.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-02
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

In the treatment of allergic reactions of mantis shrimp, the prior art is difficult to effectively utilize T cell epitope peptides, which leads to challenges in the research and development of hypoallergenic aquatic products, especially the efficacy of shrimp allergies remains to be studied.

Method used

By bioinformatics technology, 10 T cell epitope peptides of mantis tropomycin were predicted, combined with CD4+ T cell proliferation experiments and IL-2 release levels, four T cell epitope peptides without IgE responsiveness were identified. , and designed a T-cell epitope tandem peptide, which was connected in tandem with KK linker, and developed a desensitization preparation for preventing or treating shrimp allergies.

Benefits of technology

It has achieved the immune tolerance potential for shrimp allergies, provided a new vaccine development strategy, which can significantly inhibit the binding of IgE and mantis tropomyosin, significantly stimulate the proliferation of CD4+ T cells, and release a large amount of IL-2. Prove its effectiveness in the treatment of shrimp allergy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080902A_ABST
    Figure CN119080902A_ABST
Patent Text Reader

Abstract

The invention provides a T cell epitope peptide of Oratosquilla oratoria allergen tropomyosin and application thereof, the T cell epitope peptide is any one or more of the following epitope polypeptides, and the amino acid sequences of the epitope polypeptides are shown as SEQ ID NO: 1-4. According to the invention, 10 T cell epitope peptides are predicted by using bioinformatics software. Four T cell epitope peptides without IgE reactivity are identified by combining a CD4 + T cell proliferation experiment with the release level of IL-2 and a serological experiment; the T-cell epitope tandem peptide with immune tolerance potential is designed based on the T-cell epitope peptide and can be developed into a desensitization preparation for preventing or treating shrimp allergy, and a new strategy is provided for developing a food allergy immunotherapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biological immunology, and in particular relates to a T cell epitope peptide of mantis shrimp sensitizer tropomyosin and application thereof. Background Art

[0002] Oratosquilla oratoria is one of the most consumed shrimps in coastal areas of Asia, with annual catch accounting for about one-fifth of the total shrimp catch in the country. With the continuous growth of consumption of mantis shrimp, the allergic reactions caused by it deserve our attention. Tropomyosin (TM) is the main allergen of mantis shrimp and other crustacean aquatic products, and can bind to the serum of 72% to 98% of patients with crustacean food allergy. At the same time, it has the characteristics of high temperature and pressure resistance, acid and alkali resistance, etc., which is one of the main reasons restricting the research and development of low-allergenic aquatic products.

[0003] The specific binding of allergen epitopes to immune cell surface receptors is a necessary condition for inducing allergic reactions. Antigenic epitopes are mainly divided into T cell epitopes and B cell epitopes. In the process of IgE-mediated food allergy, T cell epitopes are recognized by T lymphocytes and induce the proliferation and differentiation of helper Th0 cells. Antigen-specific CD4+T cells can differentiate into Th2 cells and produce cytokines (IL-4, IL-5, IL-13), leading to the differentiation of B cells into plasma cells to produce IgE, which cross-links with FcεRI receptors on the surface of effector cells, causing severe allergic reactions in the body. T cell epitope peptides have the characteristics of being unable to cross-link with IgE and regulating the body's immune response. Therefore, peptide immunotherapy (PIT) based on T cell epitope peptides is considered to be a safe and effective strategy for the treatment of food allergies. Recombinant vaccines based on T cell epitope tandem peptides have the characteristics of low allergenicity and can be used for immune regulation. They have good effects in the treatment of dust mite allergy and pollen allergy, but their efficacy in shrimp allergy remains to be studied.

[0004] Therefore, identifying the T cell epitopes of the main allergen TM of mantis shrimp and constructing T cell epitope tandem peptides can provide a theoretical basis for the development of vaccines with immune tolerance potential. Summary of the invention

[0005] The present invention aims to solve one of the technical problems in the above-mentioned technology at least to some extent.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] A T cell epitope peptide of mantis shrimp allergen tropomyosin is any one or more of the following epitope polypeptides, and the amino acid sequence of the epitope polypeptide is shown in SEQ ID NOs: 1-4.

[0008] A T cell epitope tandem peptide for desensitization therapy is obtained by sequentially tandemly connecting four T cell epitope peptides with amino acid sequences as shown in SEQ ID NOs: 1 to 4.

[0009] Optionally, the linker of the tandem T cell epitope peptide is one or more of KK, GPGPG, LRMKLPKS, EAAAK, and GGGS.

[0010] Furthermore, the amino acid sequence of the T cell epitope tandem peptide is shown in SEQ ID NO:5.

[0011] A gene encoding the above-mentioned T cell epitope tandem peptide, the nucleotide sequence of the gene is shown in SEQ ID NO:6.

[0012] A biological material containing the above gene, wherein the biological material is a recombinant expression vector or a recombinant strain.

[0013] Use of the above T cell epitope peptide, the above T cell epitope tandem peptide or the above biomaterial in the preparation of desensitization preparations.

[0014] A polypeptide vaccine contains the above-mentioned T cell epitope peptide or the above-mentioned T cell epitope tandem peptide.

[0015] Optionally, the polypeptide vaccine further comprises a pharmaceutically acceptable adjuvant.

[0016] Compared with the prior art, the present invention provides a T cell epitope peptide of mantis shrimp allergen tropomyosin, which has the following beneficial effects:

[0017] The present invention uses bioinformatics technology to predict 10 T cell epitope peptides of exported mantis shrimp TM, using CD4 + T cell proliferation experiments combined with IL-2 release levels and serological experiments identified four T cell epitope peptides without IgE reactivity. Based on the T cell epitope peptides, a T cell epitope tandem peptide with immune tolerance potential was designed, which can be used to develop desensitization preparations for the prevention or treatment of shrimp allergies, providing a new strategy for the research and preparation of a vaccine with immune tolerance potential.

[0018] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1Distribution of primary structures of T cell epitope peptides predicted by six bioinformatics software;

[0020] Figure 2 Identification of T cell epitopes; A is CD4 + Schematic diagram of T cell proliferation experimental scheme; B is rTM and predicted T cell epitope peptide stimulation CD4 + Representative flow cytometry images of T cell proliferation; C is CD4 stimulated by rTM and predicted T cell epitope peptides + Statistical analysis of T cell proliferation; D is the ELISA method to detect the release level of IL-2 in the cell supernatant;

[0021] Figure 3 for the location of T cell epitopes on the tertiary structure of TM;

[0022] Figure 4 It is the analysis of IgE binding activity of T cell epitopes; A is the inhibitory Dot blot analysis of IgE binding activity of T cell epitopes; NC is the negative control group, PC is the positive control group, rTM and peptides T1, T8, T9, T10 are used as inhibitors to inhibit the binding of substrate rTM with IgE in the serum of patients allergic to mantis shrimp, S1-S6 are the serum of patients allergic to mantis shrimp (dilution multiple is 1:2); B is the grayscale analysis and significance analysis of the inhibitory Dot blot results;

[0023] Figure 5 Schematic diagram for designing the primary sequence of the T cell epitope tandem peptide (SEQ ID NO: 5). DETAILED DESCRIPTION

[0024] Embodiments of the present invention are described in detail below, examples of which are shown in the accompanying drawings, wherein the same or similar reference numerals throughout represent the same or similar elements or elements having the same or similar functions. The embodiments described below with reference to the accompanying drawings are exemplary and are intended to be used to explain the present invention, and should not be construed as limiting the present invention.

[0025] The disclosure below provides many different embodiments or examples to realize different implementations of the present invention. In order to simplify the disclosure of the present invention, specific embodiments or examples are described below. Of course, they are only examples, and the purpose is not to limit the present invention. In addition, the examples of various specific processes and materials provided by the present invention, those of ordinary skill in the art can be aware of the applicability of other processes and / or the use of other materials. Unless otherwise stated, the implementation of the present invention will adopt the traditional techniques in the fields of chemistry, molecular biology, etc. within the capabilities of those skilled in the art. In addition, unless otherwise stated, in this article, nucleic acids are written from left to right in the direction of 5' to 3', and amino acid sequences are written from left to right in the direction of amino terminal to carboxyl terminal.

[0026] The present invention is described below by means of illustrative specific examples, which are not intended to limit the scope of the present invention in any way. It is particularly noted that the reagents used in the present invention are commercially available unless otherwise specified.

[0027] Example 1 Prediction of T cell epitopes of mantis shrimp tropomyosin

[0028] The full-length amino acid sequence of Mantis shrimp TM (AB308320.1) was obtained from GenBank, which contains 284 amino acids. Six bioinformatics softwares, including NetMHCII pan4.0, NetMHCII 2.3, SYFPEITHI, ProPred, Rankpep, and TepiTool, were used to predict the T cell epitopes of Mantis shrimp TM. Based on the HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 alleles, namely, DRB1*01:01, DRB1*03:01, DRB1*04:01, DRB1*04:05, DRB1*07:01, DRB1*08:02, DRB1*09:01, DRB1*11:01, DRB1*12:01, DRB1*13:02, DRB1*15:01, DRB3*01:01, DRB4*01:01, and DRB5*01:01, six epitopes were predicted using NetMHCII pan4.0; 2.3 predicted 4 epitopes; SYFPEITHI predicted 8 epitopes; ProPred predicted 11 epitopes; Rankpep predicted 8 epitopes; TepiTool predicted 8 epitopes. The amino acid regions of T cell epitope peptides predicted by the above 6 bioinformatics software are shown in Table 1.

[0029] Combining the TM antigen epitope regions predicted by 6 bioinformatics software, the amino acid regions predicted by four or more software were selected as the predicted T cell epitope peptides of TM (see Figure 1 ), and finally 10 sequences were obtained (see Table 2), and the 10 predicted T cell epitope peptides were sent to Jiangsu GenScript Biotechnology Co., Ltd. for synthesis.

[0030] Table 1 Prediction information of T cell epitopes of mantis shrimp TM

[0031]

[0032]

[0033] Table 2 Information on T cell epitope synthetic peptides predicted from Mantis shrimp TM

[0034]

[0035] Example 2 Identification of T cell epitopes

[0036] like Figure 2 As shown in A, Balb / c mice were sensitized by intraperitoneal injection of rTM (recombinant mantis shrimp tropomyosin induced by pET-28a-TM strain) on the 7th and 14th days, respectively, to induce the body to produce specific IgE, and the mice were killed on the 15th day. The spleen of rTM-sensitized mice was extracted, and single-cell suspension was prepared. 5×10 7 The cells were stained with CFSE (final concentration of 5 μM). Then the sample was added to stimulate the cells, rTM was added at a final concentration of 2 μg / mL as a positive control group, and the predicted T cell epitope peptides (10 T cell epitopes in Example 1) were added at a final concentration of 500 μg / mL, and incubated in a 37°C incubator for 72 hours. The supernatant was collected for cytokine detection. The cell pellet was resuspended in buffer and used for flow cytometry to detect CD4 + T cell proliferation.

[0037] The results are as follows Figure 2 As shown in B and 2C, compared with the PBS group, rTM and peptide T1 (AA 4~24 )、T8(AA 168~183 )、T9(AA 194~212 )、T10(AA 221~243 ) can significantly stimulate CD4 + T cells proliferate and release large amounts of IL-2 cytokines ( Figure 2 D), therefore, peptides T1, T8, T9, and T10 were identified as T cell epitopes of mantis shrimp. The verified T cell epitopes were located on the tertiary structure of TM, such as Figure 3 shown.

[0038] Example 3 Analysis of IgE Binding Activity of T Cell Epitopes

[0039] The IgE binding activity of T cell epitopes was analyzed by inhibition Dot blot. The substrate was 1 μg of mantis shrimp rTM, and the primary antibody was 1 μg of T cell epitope peptide or the product of rTM and mantis shrimp allergic patient serum S1-S6 (dilution multiple 1:2) pre-incubated at 37°C for 2-3 hours, and then incubated with the substrate at room temperature for 12 hours, where rTM and T cell epitope peptide were used as inhibitors. The primary antibody of the negative control group (NC group) was the serum of mantis shrimp allergic patients, and then incubated with the substrate BSA for 12 hours. The primary antibody of the positive control group (PC group) was the serum of mantis shrimp allergic patients, and then incubated with the substrate rTM for 12 hours. Finally, Image J software was used to quantitatively analyze the spots after chemiluminescence.

[0040] The results are as follows Figure 4 As shown in the figure, compared with the PC group, rTM can significantly inhibit the binding of rTM to IgE in the serum of allergic patients, while peptides T1, T8, T9, and T10 are significantly different from the rTM group, and there is no significant difference with the PC group, indicating that peptides T1, T8, T9, and T10 cannot inhibit the binding of rTM to IgE in the serum of allergic patients. Therefore, it was verified that peptides T1, T8, T9, and T10 are T cell epitope peptides without IgE reactivity in mantis shrimp TM.

[0041] Example 4 Design and construction of T cell epitope tandem peptides

[0042] (1) Design of T cell epitope tandem peptides of mantis shrimp TM

[0043] Four T cell epitope peptides were connected in series in the order of T1 (SEQ ID NO: 1) - T8 (SEQ ID NO: 2) - T9 (SEQ ID NO: 3) - T10 (SEQ ID NO: 4), and the peptide segments were connected by lysine-lysine (KK) to form a TM T cell epitope tandem peptide, whose amino acid sequence is as follows: Figure 5 (SEQ ID NO:5).

[0044] The gene sequence encoding the T cell epitope tandem peptide of the recombinant TM was designed and named pTM, and its nucleotide sequence is:

[0045] (SEQ ID NO: 6; the bold and underlined part is the nucleotide sequence of the KK linker).

[0046] In short, the nucleotide sequences of peptides 1, T8, T9, and T10 in Table 3 were connected using a KK linker. Then, Nde I restriction site and EcoR I restriction site and termination codon TAA (270 bp in total) were added to the 5' and 3' ends of the pTM gene sequence, respectively.

[0047] Table 3 T cell epitope peptide gene sequences of Mantis shrimp TM

[0048]

[0049]

[0050] (2) Construction of T cell epitope tandem peptides of mantis shrimp TM

[0051] The non-T cell epitope peptide part was deleted by adopting the segmented cloning method, and the full-length gene of pTM was obtained after overlapping extension PCR. PrimerPrimer 5.0 software was used to design specific primers for segmented cloning of T cell epitope peptides, and the primers designed for overlapping extension PCR are shown in Tables 4 and 5. The TM gene sequence (GenBank: AB308320.1) was used as a template, and SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12 were used as primers for the first round of overlapping extension PCR; the first round of PCR product was used as a template, and SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16 were used as primers for the second round of overlapping extension PCR to obtain the gene sequence pTM.

[0052] Table 4 Specific primers for the first round of PCR used to amplify T cell epitope peptides

[0053]

[0054] Table 5 Second round PCR specific primers used to amplify T cell epitope peptides

[0055]

[0056] Note: CATATG is Nde I is the restriction site; GAATTC is the restriction site of EcoR I

[0057] Table 6 The first round of overlap extension PCR amplification system

[0058]

[0059] Table 7 PCR amplification conditions

[0060]

[0061] Table 8 The second round amplification system of the first overlap extension PCR

[0062]

[0063] Table 9 The first round amplification system of the second overlap extension PCR

[0064]

[0065] Use two restriction endonucleases, Nde I and EcoR I, to double-digest pTM for 30min to 60min (Table 10), and connect the digestion product to the expression vector pET-28a, and connect at 16℃ for 16h to 24h. The obtained ligation product was transformed into Escherichia coli cells for expression and reproduction: take 50μL of BL21 (DE3) competent cells melted on ice, add the ligation product, incubate on ice for 30min, heat shock in a 42℃ water bath for 45s, and then immediately ice bath for 2min, add 500μL of sterile LB medium without antibiotics, and culture at 37℃ and 200rpm for 1h. The culture solution is spread in a culture dish containing Kana antibiotics for reproduction. Then the positive strain is inoculated in LB medium containing Kana resistance (37℃, 200rpm) and cultured to OD 600 The value was 0.6-0.8, and the inducer IPTG with a final concentration of 1 mM was added to induce expression in a shaker (37°C, 200 rpm) for 4-5 hours to finally obtain the recombinant protein of pTM.

[0066] Table 10 Double enzyme digestion system

[0067]

[0068] Table 11 pET-28a expression vector ligation system

[0069]

[0070] In summary, 10 T cell epitope peptides were predicted by bioinformatics methods, CD4 + T cell proliferation experiments combined with IL-2 release levels and serological experiments identified four T cell epitope peptides without IgE reactivity. Based on the T cell epitope peptides, a T cell epitope tandem peptide with immune tolerance potential was designed, which can be used to develop desensitization preparations for the prevention or treatment of shrimp allergies, providing a new strategy for the development of food allergy immunotherapy.

[0071] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms should not be understood as necessarily being directed to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine different embodiments or examples described in this specification.

[0072] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. A T cell epitope peptide of tropomyosin, a mantis shrimp allergen, characterized in that: It is any one or more of the following epitope polypeptides, and the amino acid sequence of the epitope polypeptide is shown in SEQ ID NOs: 1-4.

2. A T cell epitope tandem peptide for desensitization therapy, characterized in that: The four T cell epitope peptides with amino acid sequences as shown in SEQ ID NOs: 1 to 4 in claim 1 are sequentially connected in series to obtain the T cell epitope tandem peptide.

3. The T cell epitope tandem peptide according to claim 2, characterized in that: The linker of the tandem T cell epitope peptide is one or more of KK, GPGPG, LRMKLPKS, EAAAK, and GGGS.

4. The T cell epitope tandem peptide according to claim 2, characterized in that: The amino acid sequence of the T cell epitope tandem peptide is shown in SEQ ID NO:

5.

5. The gene encoding the T cell epitope tandem peptide according to claim 4, characterized in that: The nucleotide sequence of the gene is shown in SEQ ID NO:

6.

6. A biological material containing the gene according to claim 4, characterized in that: The biological material is a recombinant expression vector or a recombinant strain.

7. Use of the T cell epitope peptide according to claim 1, the T cell epitope tandem peptide according to claim 4 or the biomaterial according to claim 6 in the preparation of a desensitization preparation.

8. A polypeptide vaccine, characterized in that: Containing the T cell epitope peptide according to claim 1 or the T cell epitope tandem peptide according to any one of claims 2-5.

9. The polypeptide vaccine according to claim 8, characterized in that The polypeptide vaccine further comprises a pharmaceutically acceptable adjuvant.

Citation Information

Cited By

  • T cell epitope peptide of tropomyosin allergen and application of T cell epitope peptide

    CN119978089A